Chromadex CORP 8-K filings

Niagen Bioscience announced Q2 2026 results with $29.8M in net sales, launched a telehealth platform, and introduced a new therapeutic candidate for rare diseases.

Niagen Bioscience, Inc. reports results from its 2026 Annual Meeting, with all director nominees elected and auditor ratification approved.

Niagen Bioscience announced first quarter 2026 financial results, with net sales reaching $31.5 million and net income of $6.3 million.

Niagen Bioscience, Inc. announced an increase in its share repurchase program authorization from $10 million to $20 million, signaling management's confidence in its long-term value.

Niagen Bioscience, Inc. reported a robust 30% year-over-year net sales increase to $129.4 million and a 103% net income surge to $17.4 million for fiscal year 2025, alongside a positive 2026 outlook.

Niagen Bioscience, Inc. announced the sale of its analytical reference standards and services business to LGC Group in an all-cash transaction, aligning with its strategy to focus on NAD+ science.

Niagen Bioscience has acquired the entire Nicotinamide Riboside (NR) patent portfolio from Queens University Belfast, consolidating its intellectual property leadership in the NAD+ industry.

Niagen Bioscience's Board of Directors approved a share repurchase program authorizing the company to buy back up to $10 million of its common stock.

Niagen Bioscience reported robust third-quarter 2025 financial results with significant revenue and profit growth, alongside an increased full-year sales forecast.

Niagen Bioscience, Inc. has increased its full-year 2025 net sales growth outlook to 25% to 30% from 22% to 27%.

Niagen Bioscience, Inc. reported strong second-quarter 2025 financial results, with net sales up 37% and net income reaching $3.6 million, leading to an increased full-year revenue outlook.

Niagen Bioscience, through its subsidiary ChromaDex, Inc., has entered into a definitive sales agreement with W. R. Grace & Co.-Conn. for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL) until at least April 2029, with provisions for a potential manufacturing license.

Niagen Bioscience, Inc. stockholders have approved significant amendments to its 2017 Equity Incentive Plan, increasing available shares by 4.75 million, and adopted a new Employee Stock Purchase Plan with 650,000 shares, enhancing employee ownership and retention.

Niagen Bioscience announces a successful first quarter in 2025, marked by a 38% increase in net sales and an improved full-year outlook.

ChromaDex Corporation has officially changed its name to Niagen Bioscience, Inc., reflecting its commitment to advancing NAD+ research and healthy-aging solutions, with its stock trading under the new ticker symbol NAGE.

ChromaDex announced a successful fiscal year 2024, marked by a 19% increase in net sales, a significant improvement in net income, and a strong cash position.

ChromaDex Corporation amends CEO Robert Fried's employment agreement, increasing his base salary and granting performance stock units tied to stock price appreciation.

ChromaDex Corporation has engaged Crowe LLP as its new independent registered public accounting firm, effective December 13, 2024, following a competitive review process.

ChromaDex has reached a supplemental agreement with Dartmouth College, waiving approximately $3.5 million in unpaid royalties and future fees, contingent on securing an appeal bond in a patent infringement case.

ChromaDex Corporation has amended its at-market issuance sales agreement, adding Roth Capital Partners as a sales agent and removing B. Riley Securities.

ChromaDex announced a strong third quarter with a 31% increase in revenue, record net income, and significant growth in Niagen ingredient sales.

ChromaDex Corporation's independent auditor, Marcum LLP, has resigned effective October 31, 2024, due to independence concerns arising from Marcum's merger with CBIZ Inc.

ChromaDex Corporation has appointed Ozan Pamir as its new Chief Financial Officer, effective October 21, 2024, replacing interim CFO James Lee.

ChromaDex announced a 12% year-over-year increase in net sales to $22.7 million, achieving near breakeven net loss and positive Adjusted EBITDA of $1.6 million for the second quarter of 2024.

ChromaDex Corporation has appointed James Lee as Interim Chief Financial Officer and Interim Principal Accounting Officer, effective July 13, 2024, following the resignation of Brianna Gerber.

ChromaDex Corporation's Chief Financial Officer, Brianna Gerber, has resigned effective July 12, 2024, but will provide consulting services until August 12, 2024, to ensure a smooth transition.

ChromaDex Corporation held its 2024 Annual Meeting of Stockholders on June 20, 2024, where all director nominees were elected and the appointment of Marcum LLP as the independent auditor was ratified.

ChromaDex reported a slight decrease in first-quarter revenue but improved profitability and reiterated its full-year revenue growth outlook of at least 16%.

ChromaDex Corp. announced its fourth quarter and fiscal year 2023 financial results, highlighting a 16% increase in full-year net sales, improved gross margins, and a significant reduction in net loss, achieving profitability in Q4.